Level D· Preclinical EvidenceAnimal Study

The regenerative potential of young versus senescent rabbit adipose-derived mesenchymal stem cells and their impact on the treatment of intervertebral disc degeneration.

Mavrogonatou E., Korompilia AM., Lampri E., Kavvadia VS., Kosmas D., Kosmas P.

Animal Study on Disc Degeneration, published in Spine J (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Spine J (2026)
Country
United States
Reported sample size
PMID
41421771
DOI
10.1016/j.spinee.2025.12.004

Abstract (original English)

Implantation of mesenchymal stem cells (MSCs) appears to be a promising choice for intervertebral disc (IVD) regeneration. Among MSCs, adipose-derived MSCs (ADSCs) have shown stronger differentiation ability towards a nucleus pulposus (NP)-like phenotype. The aim of the current study was to assess the IVD regenerative potential of rabbit ADSCs (rADSCs) in vitro and in vivo. Given that preceding propagation by serial in vitro subculturing is often required to achieve high numbers of viable cells necessary for tissue regeneration applications (which could result in senescence induction), we explored the effect of senescence on rADCSs' molecular profile and function in vitro, as well as its direct effect on the final outcome of IVD tissue quality for the first time, when injected intradiscally in a rabbit model. The molecular profile of isolated young and senescent rADSCs was assessed in vitro, before their delivery into rabbit lumbar IVDs to explore differences regarding their effect on IVD tissue quality. Alcian Blue, Oil Red O and Alizarin Red S staining procedures were performed for the in vitro determination of young and senescent rADSCs' chondrogenic, adipogenic and osteogenic capacity, respectively. Assessment of rADSCs' viability, cell cycle progression and activation of selected biochemical pathways after hyperosmotic treatment was performed by the MTT assay, by flow cyto

What this study does not prove

  • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsRabbitsIntervertebral Disc DegenerationMesenchymal Stem CellsCellular SenescenceRegenerationAdipose TissueMesenchymal Stem Cell TransplantationIntervertebral DiscCell Differentiation

Related research